Navigation Links
FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)
Date:2/27/2009

ult in chronic airway inflammation(4) and progressive loss of lung function, making it difficult to breathe normally.(4,6)

The FDA approval is based on two pivotal (Phase III) efficacy and safety trials, SHINE and SUN, which evaluated more than 3,600 patients ages 40 years and older with moderate to very severe COPD. (2) These studies demonstrated that patients using SYMBICORT pMDI 160/4.5 mcg had significantly greater mean improvements from baseline in pre-dose forced expiratory volume in one second (FEV1) averaged over the treatment period compared with formoterol 4.5 mcg and placebo.(2)

In addition, patients using SYMBICORT had significantly greater mean improvements from baseline in 1-hour post-dose FEV1 averaged over the treatment period compared with budesonide 160 mcg and placebo.(2) Furthermore, the median time to onset of significant bronchodilation (greater than or equal to 15% improvement in FEV1) was five minutes.(1)

SYMBICORT was generally well-tolerated over the 12-month study,(2) and the incidence of pneumonia was no different for SYMBICORT compared to placebo.(2) There was a higher incidence of potential lung infections other than pneumonia (e.g., bronchitis and viral lower respiratory tract infections) in patients receiving SYMBICORT 160/4.5 mcg than in those receiving formoterol 4.5 mcg or placebo.(2) The most common drug-related adverse events reported were nasopharyngitis (the common cold), oral candidiasis, bronchitis, sinusitis and viral upper respiratory tract infection.(2)

"Through these pivotal studies, SYMBICORT demonstrated rapid and sustained improvements in lung function and was generally well-tolerated long-term for patients with moderate to severe COPD,"(2) said lead investigator Dr. Donald Tashkin of the University of California, Los Angeles (UCLA). "Healthcare professionals and patients with severe COPD can now consider using SYMBI
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen
2. European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
3. Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
4. FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
5. FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers
6. FDA Approves KAPIDEX(TM) (Dexlansoprazole) delayed release capsules for the Treatment of GERD
7. Bion Announces PENNVEST Board Approves $7.8 Million Financing for Kreider Farms Dairy Project
8. Monsanto Board Approves 10 Percent Dividend Increase
9. FDA Approves Most Comprehensive System to Test Donated Blood for HIV, Hepatitis B & Hepatitis C
10. MultiVu Video Feed: U.S Food and Drug Administration (Fda) Approves Latisse(TM) --
11. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... YORK , March 27, 2015   ... in liquid photopurification, announced today that the Company ... for the continued trading of SurePure ("SURP") securities ... venture marketplace for entrepreneurial and development stage companies. ... Group introduced standards and eligibility requirements designed to ...
(Date:3/27/2015)... SHANGHAI , March 27, 2015 ... a leading open-access R&D capability and technology platform ... device industries, announced today that an Investigational New ... monoclonal antibody for rheumatoid arthritis has been accepted ... Administration (CFDA).  In September 2012, ...
(Date:3/26/2015)... Bioscience, Inc. (NASDAQ: ROKA ), a molecular ... for the detection of foodborne pathogens, today reported ... full year ended December 31, 2014. ... ended December 31, 2014 was $1.4 million compared ... and $1.5 million for the third quarter of ...
(Date:3/26/2015)... CO (PRWEB) March 26, 2015 The ... has formed a strategic alliance with Designing Gig LLC ... their clients. , “Forging this alliance with ... Now we can extend a comprehensive, end-to-end, digital ... development, strategy, and execution,” said Chuck Miller, president of ...
Breaking Biology Technology:SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2
... Bulletin Board: DSCI), a provider of advanced wound care ... based on a,number of new products that are finding ... direct salespersons in the US a year ago, now,has ... increase is a significant one,for Derma Sciences, which has ...
... pre-adoption clinical evaluation of ... Recent case of vCJD now means that all the population is susceptible to ... the disease, - Increased concerns over "second wave" of vCJD in individuals with much ... longer incubation times - P-Capt(R) prion reduction filter still the only proven method ...
... 17, 2008 Scientific studies on climate change, energy ... more than 145 million processing hours on supercomputers at ... Innovative and Novel Computational Impact on Theory and Experiment ... industry, academia and government research facilities receive access to ...
Cached Biology Technology:Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008 2Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008 3ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 2ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 3ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 4ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 5Oak Ridge leads DOE INCITE effort in 2008 2Oak Ridge leads DOE INCITE effort in 2008 3Oak Ridge leads DOE INCITE effort in 2008 4
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation (OTCQX: ... exhibition for service robots ever held in ... place on May 11-13, 2015 at the Javits ... for the event include: Acorn Product Development; Axis ... Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya Systems ...
(Date:3/12/2015)... , March 12, 2015 ... a standardized identity and access management (IAM) solution ... implementation schedule. With Beta System,s new IAM package, ... best practices gleaned from multiple IAM implementations across ... the software as well as any necessary services ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... allow women diagnosed with cancer the opportunity to have children ... researchers at the University of Michigan Comprehensive Cancer Center have ... cancer treatments, a woman can preserve the hope of one ... thawing them safely so they can lead to pregnancy is ...
... cause of death among children in developing regions of ... or international health organizations and charities, according to investigators ... of pediatric cancer is occurring as the number of ... the efforts of the World Health Organization and international ...
... critical inhibitory step that is a key component ... neutrophil production and destruction. The research, published in ... process for disposal of dying neutrophils is actively ... the processes that control neutrophil turnover may contribute ...
Cached Biology News:Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment 2Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment 3Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 2Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 3White Blood Cell 'Waste Disposal' System Plays Critical Regulatory Role 2
Apoptosis Detection Systems and Reagents...
...
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
Biology Products: